Approved for adults with multiple myeloma (MM) — in combination with dexamethasone, and as maintenance therapy after autologous stem cell transplant — and for myelodysplastic syndromes (MDS) with deletion 5q (del(5q)) cytogenetic abnormality, and for certain mantle cell lymphoma (MCL) and follicular lymphoma patients (in combination with rituximab).